Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.

Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.

Why Is HealthEquity (HQY) Down 10% Since Last Earnings Report?

by Zacks Equity Research

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why HealthEquity (HQY) is Poised for a Turnaround After Losing 7.7% in 4 Weeks

by Zacks Equity Research

HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

by Zacks Equity Research

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

by Zacks Equity Research

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.

BD (BDX) to Expand Base in Pharmacy Automation With New Buyout

by Zacks Equity Research

BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.

HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.

Here's Why You Should Hold on to Avanos (AVNS) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

HealthEquity (HQY) Q1 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Assure Holdings Corp. (IONM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -216.67% and 27.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q1 Earnings Beat Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.

HealthEquity (HQY) Q4 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: HealthEquity (HQY) Q4 Earnings Expected to Decline

by Zacks Equity Research

HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. (GDRX) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of -10% and 1.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ModivCare (MODV) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of 28.66% and 4.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Gets FDA Approval for CardioMEMS HF System

by Zacks Equity Research

Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.

Here's Why You Should Hold on to STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.